1. Receptor Tyrosine Kinase Signaling Favors a Protumorigenic State in Breast Cancer Cells by Inhibiting the Adaptive Immune Response
- Author
-
Elton Rexhepaj, Dongmei Zuo, Donal J. Brennan, Ciriaco A. Piccirillo, Eva Bjur, Sean Cory, Tony Pawson, Josie Ursini-Siegel, Babette Schade, William R. Hardy, David G. DeNardo, Sonya Lam, Michael Hallett, Lisa M. Coussens, William M. Gallagher, Morag Park, Karin Jirström, and William J. Muller
- Subjects
CD4-Positive T-Lymphocytes ,Cancer Research ,T-Lymphocytes ,Breast Neoplasms ,Mice, Transgenic ,Article ,Receptor tyrosine kinase ,Mice ,Immune system ,Pregnancy ,medicine ,Animals ,Humans ,RNA, Neoplasm ,Oligonucleotide Array Sequence Analysis ,Proportional Hazards Models ,Immunosuppression Therapy ,Mammary tumor ,biology ,Mammary Neoplasms, Experimental ,Receptor Protein-Tyrosine Kinases ,Cancer ,medicine.disease ,Acquired immune system ,Parity ,CTL ,Treatment Outcome ,Shc Signaling Adaptor Proteins ,Oncology ,Immunology ,biology.protein ,Cancer research ,Female ,Breast disease ,Signal transduction ,Signal Transduction - Abstract
Using transgenic mouse models of breast cancer that ablate Src homology and collagen A (ShcA) expression or oncogene-coupled ShcA signaling, we previously showed that this adaptor is critical for mammary tumor onset and progression. We now provide the first evidence that ShcA regulates mammary tumorigenesis, in part, through its ability to regulate the adaptive immune response. Inactivation of ShcA signaling within tumor cells results in extensive CD4+ T-cell infiltration and induction of a humoral immune response in mammary tumors. This is associated with a robust CTL response in preneoplastic lesions that are deficient in ShcA signaling. Moreover, mammary tumor progression of ShcA-deficient hyperplasias is accelerated in a T cell–deficient background. We also uncover a clinically relevant correlation between high ShcA expression and low CTL infiltration in human breast cancers. Finally, we define a novel ShcA-regulated immune signature that functions as an independent prognostic marker of survival in human epidermal growth factor receptor 2+ and basal breast cancers. We reveal a novel role for tumor cell–derived ShcA in the establishment and maintenance of an immunosuppressive state. Cancer Res; 70(20); 7776–87. ©2010 AACR.
- Published
- 2010
- Full Text
- View/download PDF